SANTA CRUZ, Calif., March 16, 2026
Unnatural Products has announced the successful closing of a $45 million Series B financing round, marking a significant step forward in the development of macrocyclic peptide therapeutics targeting historically “undruggable” disease pathways. The funding round was led by The Venture Collective with participation from major investors including Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, and Droia Ventures, highlighting strong investor confidence in next-generation therapeutic platforms
Investment to Accelerate Drug Discovery Platform
The newly secured capital will be strategically deployed to expand Unnatural Products’ proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics. These therapeutics are specifically designed to address complex intracellular targets that have traditionally been inaccessible using conventional small molecules or biologics. The company’s innovative approach combines computational design, automated chemistry, and high-throughput biological testing, enabling rapid progression from early discovery to optimized drug candidates
This financing also supports the company’s ambition to transition its lead programs toward clinical development, a critical milestone in the pharmaceutical lifecycle. By focusing on scalability and precision, the platform is positioned to improve both drug efficacy and development timelines, making it highly relevant for stakeholders in regulated pharmaceutical environments.
Enabling Early Detection and Precision Medicine in Neurology
Advertisement
The panel is designed to support early and pre-symptomatic detection of neurological disorders, leveraging ultra-high sensitivity and specificity to detect low-abundance biomarkers in minimally invasive samples. This capability is particularly important for diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis, where early diagnosis remains a major unmet need. The platform is also compatible with automated workflows using the ARGO™ HT System, ensuring high reproducibility, scalability, and ease of use in both research and clinical settings.
By enabling large-scale, high-resolution analysis of protein biomarkers, the NULISA platform facilitates the identification of prognostic indicators, therapeutic response markers, and co-pathologies, accelerating the transition from basic research to clinical applications and precision medicine strategies.
Macrocyclic Peptides: A Next-Generation Therapeutic Modality
Macrocyclic peptides are emerging as a powerful new class of therapeutics, offering a unique combination of the selectivity of biologics and the delivery advantages of small molecules. This hybrid capability allows for oral delivery options, which could significantly reduce reliance on injectable therapies and improve patient compliance. According to company leadership, the platform enables targeting of intracellular pathways that have remained out of reach for decades, opening new opportunities in areas such as cardiometabolic, inflammatory, and immunological diseases.
Importantly, this modality is gaining traction across the pharmaceutical industry due to its ability to bridge critical gaps in drug discovery, especially for high-value targets that were previously considered non-viable. This positions Unnatural Products at the forefront of innovative therapeutic development, with potential long-term implications for both clinical outcomes and regulatory pathways.
Strategic Collaborations and Future Clinical Progression
In addition to the financing, Unnatural Products has established strategic collaborations with leading pharmaceutical companies, including Novartis, Merck, BridgeBio, and argenx. Notably, a recent licensing agreement with Novartis includes up to $100 million upfront and $1.7 billion in potential milestone payments, underscoring the commercial and scientific value of the platform.
These partnerships are expected to accelerate the translation of early-stage research into clinically viable therapies, reinforcing the company’s position within the global biopharmaceutical ecosystem. As the pipeline advances, the transition from discovery to clinical trials will bring increased relevance to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP) frameworks, making this development particularly significant for regulatory and quality professionals.
The $45 million Series B financing represents a pivotal moment for Unnatural Products as it advances a cutting-edge therapeutic platform aimed at solving some of the most challenging problems in drug discovery. With strong investor backing, strategic partnerships, and a clear path toward clinical development, the company is well-positioned to contribute to the next wave of pharmaceutical innovation. This announcement not only reflects growing interest in macrocyclic peptide therapeutics but also highlights the increasing role of venture capital in shaping the future of the biopharma industry.
Source: Unnatural Products, Inc. press release
